|
1
|
Liang Y, Ketchum NS, Louden C, et al: The
use of the finasteride-adjusted Prostate Cancer Prevention Trial
Prostate Cancer Risk Calculator in a Mexican referral population: a
validation study. Urol Int. 89:9–16. 2012. View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
3
|
Cooperberg MR, Broering JM and Carroll PR:
Risk assessment for prostate cancer metastasis and mortality at the
time of diagnosis. J Natl Cancer Inst. 16:878–887. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Major JM, Norman Oliver M, Doubeni CA, et
al: Socioeconomic status, healthcare density, and risk of prostate
cancer among African American and Caucasian men in a large
prospective study. Cancer Causes Control. 23:1185–1191. 2012.
View Article : Google Scholar
|
|
5
|
Lee EW, Marien T, Laze J, Agalliu I and
Lepor H: Comparison of health-related quality-of-life outcomes for
African-American and Caucasian-American men after radical
prostatectomy. BJU Int. 110:1129–1133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parker PM, Rice KR, Sterbis JR, et al:
Prostate cancer in men less than the age of 50: a comparison of
race and outcomes. Urology. 78:110–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seligson DB, Hongo F, Huerta-Yepez S, et
al: Expression of X-linked inhibitor of apoptosis protein is a
strong predictor of human prostate cancer recurrence. Clin Cancer
Res. 15:6056–6063. 2007. View Article : Google Scholar
|
|
8
|
Chen C, Chen J and Zhao KN: Editorial:
Signalling pathways in anti-cancer drug resistance. Curr Med Chem.
21:3007–3008. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gomella LG: Addressing the needs of the
high-risk prostate cancer patient. Rev Urol. 7:S18–S28.
2005.PubMed/NCBI
|
|
10
|
Chodak G: Prostate cancer: epidemiology,
screening, and biomarkers. Rev Urol. 8 Suppl:S3–S8. 2006.PubMed/NCBI
|
|
11
|
Shariat SF, Semjonow A, Lilja H, et al:
Tumor markers in prostate cancer I: blood-based markers. Acta
Oncol. 50 Suppl:61–75. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McGuire SE, Lee AK, Cerne JZ, et al: PSA
response to neoadjuvant androgen deprivation therapy is a strong
independent predictor of survival in high-risk prostate cancer in
the dose-escalated radiation therapy era. Int J Radiat Oncol Biol
Phys. 85:e39–e46. 2013. View Article : Google Scholar
|
|
13
|
Masieri L, Minervini A, Vittori G, et al:
The role of free to total PSA ratio in prediction of extracapsular
tumor extension and biochemical recurrence after radical
prostatectomy in patients with PSA between 4 and 10 ng/ml. Int Urol
Nephrol. 44:1031–1038. 2012. View Article : Google Scholar
|
|
14
|
Elmore S: Apoptosis: a review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Horak P, Pils D, Haller G, et al:
Contribution of epigenetic silencing of tumor necrosis
factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL
resistance and ovarian cancer. Mol Cancer Res. 3:335–343. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thomas LR, Bender LM, Morgan MJ and
Thorburn A: Extensive regions of the FADD death domain are required
for binding to the TRAIL receptor DR5. Cell Death Differ.
13:160–162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramaswamy M, Efimova EV, Martinez O, et
al: IG20 (MADD splice variant-5), a proapoptotic protein, interacts
with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing
recruitment of FADD and caspase-8 to the DISC. Oncogene.
23:6083–6094. 2004. View Article : Google Scholar
|
|
18
|
Thomas LR, Henson A, Reed JC, Salsbury FR
and Thorburn A: Direct binding of Fas-associated death domain
(FADD) to the tumor necrosis factor-related apoptosis-inducing
ligand receptor DR5 is regulated by the death effector domain of
FADD. J Biol Chem. 279:32780–32785. 2004. View Article : Google Scholar
|
|
19
|
Cooper WA, Kohonen-Corish MR, Zhuang L, et
al: Role and prognostic significance of tumor necrosis
factor-related apoptosis-inducing ligand death receptor DR5 in
nonsmall-cell lung cancer and precursor lesions. Cancer.
113:135–142. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhuang L, Lee CS, Scolyer RA, et al:
Progression in melanoma is associated with decreased expression of
death receptors for tumor necrosis factor-related
apoptosis-inducing ligand. Hum Pathol. 37:1286–1294. 2006.
View Article : Google Scholar
|
|
21
|
Ganten TM, Sykora J, Koschny R, et al:
Prognostic significance of tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL) receptor expression in patients
with breast cancer. J Mol Med (Berl). 87:995–1007. 2009. View Article : Google Scholar
|
|
22
|
Maduro JH, Noordhuis MG, ten Hoor KA, et
al: The prognostic value of TRAIL and its death receptors in
cervical cancer. Int J Radiat Oncol Biol Phys. 75:203–211. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van Geelen CM, Westra JL, de Vries EG, et
al: Prognostic significance of tumor necrosis factor-related
apoptosis-inducing ligand and its receptors in adjuvantly treated
stage III colon cancer patients. J Clin Oncol. 24:4998–5004.
2006.
|
|
24
|
Seligson D, Horvath S, Huerta-Yepez S, et
al: Expression of transcription factor Yin Yang 1 in prostate
cancer. Int J Oncol. 27:131–141. 2005.PubMed/NCBI
|
|
25
|
Baritaki S, Huerta-Yepez S, Sakai T,
Spandidos DA and Bonavida B: Chemotherapeutic drugs sensitize
cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and
inhibition of Yin Yang 1. Mol Cancer Ther. 6:1387–1399. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baritaki S, Suzuki E, Umezawa K, et al:
Inhibition of Yin Yang 1-dependent repressor activity of DR5
transcription and expression by the novel proteasome inhibitor
NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer
cells. J Immunol. 180:6199–6210. 2008. View Article : Google Scholar
|
|
27
|
Huerta-Yepez S, Vega M, Escoto-Chavez SE,
et al: Nitric oxide sensitizes tumor cells to TRAIL-induced
apoptosis via inhibition of the DR5 transcription repressor Yin
Yang 1. Nitric Oxide. 20:39–52. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vanaja DK, Cheville JC, Iturria SJ and
Young CY: Transcriptional silencing of zinc finger protein 185
identified by expression profiling is associated with prostate
cancer progression. Cancer Res. 63:3877–3882. 2003.PubMed/NCBI
|
|
29
|
Wallace TA, Prueitt RL, Yi M, et al: Tumor
immunobiological differences in prostate cancer between
African-American and European-American men. Cancer Res. 68:927–936.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu P, Ramachandran S, Ali Seyed SM, et
al: Sex-determining region Y box 4 is a transforming oncogene in
human prostate cancer cells. Cancer Res. 66:4011–4019. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo J, Duggan DJ, Chen Y, et al: Human
prostate cancer and benign prostatic hyperplasia: molecular
dissection by gene expression profiling. Cancer Res. 61:4683–4688.
2001.PubMed/NCBI
|
|
32
|
Han M, Snow PB, Epstein JI, Chan TY, Jones
KA, Walsh PC and Partin AW: A neural network predicts progression
for men with gleason score 3+4 versus 4+3 tumors after radical
prostatectomy. Urology. 56:994–999. 2000. View Article : Google Scholar
|
|
33
|
Yu YP, Landsittel D, Jing L, et al: Gene
expression alterations in prostate cancer predicting tumor
aggression and preceding development of malignancy. J Clin Oncol.
22:2790–2799. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oliver PG, LoBuglio AF, Zhou T, et al:
Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Breast Cancer Res Treat. 133:417–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sharma S, de Vries EG, Infante JR, et al:
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody
LBY135 alone and in combination with capecitabine in patients with
advanced solid tumors. Invest New Drugs. 32:135–144. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zinonos I, Labrinidis A, Lee M, et al:
Apomab, a fully human agonistic antibody to DR5, exhibits potent
antitumor activity against primary and metastatic breast cancer.
Mol Cancer Ther. 8:2969–2980. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baritaki S, Katsman A, Chatterjee D, et
al: Regulation of tumor cell sensitivity to TRAIL-induced apoptosis
by the metastatic suppressor Raf kinase inhibitor protein via Yin
Yang 1 inhibition and death receptor 5 up-regulation. J Immunol.
179:5441–5453. 2007. View Article : Google Scholar
|
|
38
|
Miyata Y, Watanabe S, Sagara Y, et al:
High expression of HuR in cytoplasm, but not nuclei, is associated
with malignant aggressiveness and prognosis in bladder cancer. PLoS
One. 8:e590952013. View Article : Google Scholar
|
|
39
|
Keane MM, Ettenberg SA, Nau MM, Russell EK
and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in
breast cell lines. Cancer Res. 59:734–741. 1999.PubMed/NCBI
|
|
40
|
Elrod HA, Fan S, Muller S, et al: Analysis
of death receptor 5 and caspase-8 expression in primary and
metastatic head and neck squamous cell carcinoma and their
prognostic impact. PLoS One. 5:e121782010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sung B, Ravindran J, Prasad S, Pandey MK
and Aggarwal BB: Gossypol induces death receptor-5 through
activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer
cells to TRAIL. J Biol Chem. 12:35418–35427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chang MS, Lee HS, Lee BL, et al:
Differential protein expression between esophageal squamous cell
carcinoma and dysplasia, and prognostic significance of protein
markers. Pathol Res Pract. 201:417–425. 2005. View Article : Google Scholar
|
|
43
|
Oikonomou E and Pintzas A: The TRAIL of
oncogenes to apoptosis. Biofactors. 39:343–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Deng Z, Cao P, Wan MM and Sui G: Yin Yang
1: a multifaceted protein beyond a transcription factor.
Transcription. 1:81–84. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pilarsky C, Wenzig M, Specht T, Saeger HD
and Grützmann R: Identification and validation of commonly
overexpressed genes in solid tumors by comparison of microarray
data. Neoplasia. 6:744–750. 2004. View Article : Google Scholar
|
|
46
|
Zamai L, Ahmad M, Bennett IM, et al:
Natural killer (NK) cell-mediated cytotoxicity: differential use of
TRAIL and Fas ligand by immature and mature primary human NK cells.
J Exp Med. 188:2375–2380. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Anees M, Horak P, El-Gazzar A, Susani M,
Heinze G, Perco P, Loda M, Lis R, Krainer M and Oh WK:
Recurrence-free survival in prostate cancer is related to increased
stromal TRAIL expression. Cancer. 117:1172–1182. 2011. View Article : Google Scholar : PubMed/NCBI
|
